Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have sh...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hepatol Commun
Asıl Yazarlar: Wang, Fang, Bank, Thomas, Malnassy, Gregory, Arteaga, Maribel, Shang, Na, Dalheim, Annika, Ding, Xianzhong, Cotler, Scott J., Denning, Mitchell F., Nishimura, Michael I., Breslin, Peter, Qiu, Wei
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983153/
https://ncbi.nlm.nih.gov/pubmed/29881824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1181
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller